Neo7 for Advanced and Treatment-Resistant Cancer: When You Have Done Everything and Still Feel Unstable

← All postsCancer Care7 min read

Neo7 for Advanced and Treatment-Resistant Cancer: When You Have Done Everything and Still Feel Unstable

By Alicia Hickson, MSPAS, PA-C · Certified Functional Medicine Practitioner · Founder, Rayma Health, Minnetonka, Minnesota

If you have been through chemotherapy, radiation, immunotherapy, or surgery, added IV vitamin C, mistletoe, or curcumin, taken metformin or another repurposed medication, changed the way you eat, and still feel unstable, uncertain, or at risk, nothing was done wrong. Cancer adapts. Neo7 peptide therapy is built for exactly this point in the road: it reads what your cancer’s signaling is doing right now, from your blood and urine, and designs a set of peptides to correct it. I prescribe Neo7 at Rayma Health inside a whole metabolic approach to cancer. I wrote about what Neo7 is and how it is made last month. This post is about the patient who has already done a great deal, what the weeks before the first dose are for, and what Neo7 says makes a response more likely.

Who this is for

Most people who come to Neo7 are not at the start. Neo7 describes its typical patient this way:

• Stage 3 or stage 4 cancer.
• Recurrent cancer, or cancer that has stopped responding to treatment.
• Someone who “did everything” and still feels unstable.
• High inflammation or a suppressed immune system.
• A complex case with Lyme, mold, or a viral burden underneath the cancer.
• Someone who wants deeper personalization than a protocol can give.

If that is you, the rest of this post is written for you.

Why what you did may not have lasted

Cancer is not just a tumor. It is a system: immune dysfunction, chronic inflammation, metabolic disruption, mitochondrial stress, new blood vessel growth, resistance signaling, and cells communicating in ways they should not. Most treatments hit one of those at a time, and many of them work from a biopsy taken months or years ago. Meanwhile the cancer keeps changing. It learns to hide from the immune system, and it switches on pathways that keep it alive when a treatment is pressing on it.

That is why a plan can be good and still stop holding. The pathways that should correct themselves have stopped self-correcting. Neo7 was designed for that gap.

What Neo7 does at this point

Neo7 reads your tumor and your system as they are today, on several layers at once, from a blood and urine sample: your tumor’s DNA and RNA, the proteins it is making, the signals it is sending, and your HLA type, the “display windows” your immune cells use to recognize a target. From that picture it picks the targets that matter most for you, commonly 10 to 14 or more, and designs a pooled set of peptides built for you alone, aimed at:

• Immune visibility. Helping your immune system see a tumor that has learned to hide.
• Resistance pathways. Correcting why the resistance exists, not working around it.
• Inflammatory chaos. Calming the signaling that keeps the terrain hostile.
• Mitochondrial stress and repair. Supporting energy production and repair signaling.

Your Health Index report comes with more than the peptide design. It includes off-label medication strategies, IV therapy recommendations, nutrient support, immune and metabolic strategies, and inflammation guidance matched to your targets. Neo7 calls this a hub strategy. Picture a wheel: every therapy you are doing is a spoke, and Neo7 sits at the hub, coordinating the signaling so the spokes line up. What you are already doing stays in your plan. Neo7 is added to it, and the report tells us how the pieces fit.

The 11 weeks are preparation, not waiting

From the day we collect your samples to your first dose is about 10 to 11 weeks. Patients hear that number and feel the clock. Here is what is actually happening, and what we do with the time.

WeekWhat Neo7 is doingWhat we are doing at Rayma

Week 1

Blood and urine collected and sent to the lab

Terrain labs drawn with the Neo7 samples: fasting insulin, hs-CRP, vitamin D, ferritin, a full thyroid panel, and your glucose-ketone index if you are on a metabolic diet

Weeks 1–5

Whole-exome, RNA, proteomic, and HLA analysis

Stabilizing inflammation and blood sugar: protein first, a diet matched to your cancer and your labs, sleep on a fixed wake time

Weeks 5–10

Peptide design, then manufacturing at a cGMP compounding pharmacy

Supporting detox and the gut, strengthening the immune system, and adding IV therapy when your labs give us a reason

Weeks 6–8

Your Health Index report is ready for provider review

We read your report together and fold its recommendations into your plan

Week 11

First administration

Your body is ready for the peptides, not just waiting for them

The reason this matters is simple. Neo7 is non-cytotoxic. It does not kill cells on its own; it works through your immune system and your signaling. So the state of your terrain when the peptides arrive, your inflammation, your insulin, your nutrition, your sleep, shapes how much ground the peptides have to work with. We spend those weeks building it.

What starting is like

We start low and slow. The first week’s doses are a fraction of a vial, given as small injections under the skin and into the muscle, two of each a week, and we step the dose up each week until you are on a full vial around week five. Most patients give the injections at home after training. On infusion days, the peptides go into a saline bag and run over about an hour, after any IV vitamin C or artesunate you are getting that day. In aggressive or late-stage cancers the dose can be stepped higher than one vial.

Some patients feel the regulation happen. Neo7 calls these signal effects: tiredness, a rash, feeling “wired,” and rarely a mild fever. They usually mean the body is regulating faster than it can keep up with, and they settle within 48 to 72 hours once we reduce the dose a little or put two or three days between doses. That is how we find your dose. We re-check labs by week eight or nine at the latest and adjust from there. Neo7 peptides are generally not paused once started; the main exception is a pending surgery or procedure.

How we will know it is working

A scan is one measure, and it is not the first one to move. Signaling changes before imaging does. So we look at several things together, which is the same way Neo7 tracks its own results:

• How you feel and function: energy, pain, appetite, clear thinking, stamina, mobility.
• Your labs: inflammation, blood sugar and insulin, immune markers, cancer markers.
• ctDNA, the circulating tumor DNA in your blood.
• Imaging, when it is due.
• Neo7’s own repeat testing, every 4 to 10 months, which shows whether your original targets are still the right ones or the design should be refined. A redesign means your biology moved and we moved with it.

Neo7 reports disease stabilization in more than 75% of its patients within 5 to 9 months of starting, in a population that is mostly stage 3 and 4 and heavily pretreated, and it is clear that those results reflect each patient’s whole plan, not one therapy by itself. We measure you against your own baseline, not a population average.

What makes a response more likely

Neo7 has looked at who does well and who does not across the patients it has tracked. This is the part I want you to read twice, because most of it is in your hands.

Patients who respond better tend to:

• Start earlier in the course of the disease.
• Finish the full peptide course without interruption. Neo7 names stopping early among the factors tied to poorer outcomes, and it commonly happens when a patient switches to a clinical trial or a competing therapy partway through.
• Keep the plan coordinated. One plan, one set of goals, everyone pulling the same direction.
• Keep nutrition, metabolism, and immunity supported. This is the work we start in the 11 weeks and never stop.
• Have real emotional support. Neo7 lists unresolved stress, trauma, and a nervous system stuck in fight-or-flight among the factors tied to poorer outcomes. I have seen it in my own patients. Fear and grief change what happens in a body, and so do peace and hope. That is why I ask how you are really doing at every visit, and why we treat that with the same seriousness as a lab value.

One fact to know before you start: being on Neo7 may affect your eligibility for some clinical trials. If a trial is part of your thinking, tell me at the first visit so we can sequence the plan on purpose.

How to start

If you or someone you love has advanced or recurrent cancer and you want to know whether Neo7 belongs in the plan now, book a visit. Bring everything: your pathology, your scans, every treatment you have had and what your body did with it, and your supplement list. There is no washout before Neo7 testing. You keep taking what you are taking, and we document all of it. I see patients in person at Rayma Health in Minnetonka, Minnesota. You can also message me through the patient portal or call the office at (612) 324-6338.

Cure is a hope I hold for every person who sits across from me. We fix the terrain, we add the right tools with a reason, and we give the body every chance to heal.

Frequently asked questions

Is it too late for Neo7 if I have stage 4 cancer?

Most Neo7 patients come with stage 3 or 4 cancer and prior treatment. Neo7’s results are reported from that population. Starting sooner rather than later is one of the things Neo7 ties to a better response.

Do I have to stop anything before Neo7 testing?

No. There is no washout of medications, supplements, peptides, chemotherapy, immunotherapy, or integrative treatments before your blood and urine are collected. We write down everything you are taking so the analysis is read in context.

What happens during the 11 weeks before my first dose?

Neo7 runs your whole-exome, RNA, protein, and HLA analysis, designs your peptides, and has them manufactured. We use those weeks to stabilize inflammation and blood sugar, support detox and the gut, strengthen your immune system, and set up your sleep and nutrition, so your body is ready when the peptides arrive.

How quickly will I feel different?

It varies. Some patients notice steadier energy and clearer thinking; others feel signal effects first as the dose steps up. We measure response in several places, your symptoms, your labs, ctDNA, and imaging, rather than by any one of them.

What if I feel worse after a dose?

Tell me. Tiredness, a rash, feeling “wired,” or a mild fever within a day or two of a dose are usually signal effects, and they usually settle within 48 to 72 hours once we lower the dose a little or space the doses out. Feeling worse is not a sign the therapy is working; it is a sign the dose needs adjusting.

Do I keep my other cancer treatments?

Yes. Neo7 is added to your plan. Your Health Index report includes medication, IV, and nutrient recommendations matched to your targets, and we coordinate the whole picture.

Does Neo7 affect clinical trial eligibility?

It can. If a trial is on your mind, we plan the sequence together at the first visit.

How often is testing repeated?

Every 4 to 10 months on the cancer pathway. Repeat testing shows whether your original targets are still the right ones or whether the peptide design should be refined as your biology changes.

Done everything and still not stable?

Bring your whole history to a visit.

I see patients in person at Rayma Health in Minnetonka. We go through everything you have tried, what your body did with it, and your labs, and decide together whether Neo7 belongs in your plan now.

Book a visitCall (612) 324-6338

Educational content, not personal medical advice. Neo7 peptide therapy is prescribed under an IRB-approved protocol and is not FDA-approved; no outcome is promised, and one patient's result does not predict another's. Alicia Hickson prescribes Neo7 at Rayma Health. The patient profile, process, dosing schedule, response framework, and reported results are Neo7Bioscience's, summarized here with attribution; Neo7 and PBIMA are trademarks of Neo7Bioscience, Inc. Bring your questions to a visit so we can look at your history and your plan together.

Sources

• Neo7Bioscience. The Neo7 Precision Approach to Cancer Care: A Multi-Target, Multi-Omic Strategy Built From Your Biology (provider document, 2026): the typical patient (completed conventional and integrative therapies, still unstable); cancer as an adaptive system; the multi-omic layers (RNA, ctDNA, proteomics, exosomal signaling, HLA); 6–14+ targets; the hub-strategy concept; the contents of the analysis (off-label medication, IV, nutrient, immune, metabolic, and inflammation guidance); the 11-week timeline and “preparation, not waiting”; who benefits most; non-cytotoxic; IRB-based, not FDA-approved; possible effect on clinical-trial eligibility.
• Neo7Bioscience. Clinical Outcomes Framework in Precision Multi-Omic Peptide Therapeutics: A Provider-Facing Overview: multi-dimensional response endpoints (quality of life, disease stabilization, molecular markers, imaging, time-based metrics, durability); outcomes are multifactorial and reflect the whole plan; positive predictors (earlier initiation, complete protocol without interruption, coordinated care, nutritional/metabolic/immune support, psychosocial support); factors tied to poorer outcomes (advanced burden, premature discontinuation, commonly for a clinical trial or competing intervention, fragmented care, unresolved psychological stress and persistent sympathetic activation, inadequate support).
• Neo7Bioscience. Neo7Bioscience Objective Response Rate (provider document, Revised 2025): disease stabilization in more than 75% of patients within 5–9 months of starting.
• Neo7Bioscience. Peptide Administration Guidelines, Cancer (provider document): rotating SC/IM dosing stepping up weekly to a full vial by week five; two SC and two IM injections plus one to two infusions per week; infusion in 500 mL saline over about one hour after IV vitamin C or artesunate; up to 2–3 vials per dose in aggressive or late-stage cancer; lab re-evaluation by weeks 8–9; signal effects (fatigue, rash, feeling “wired,” rare mild fever) resolving within 48–72 hours after a 0.1–0.2 mL reduction or 2–3 day spacing; peptides generally not held except for pending procedures.
• Neo7Bioscience website, Patients: the cancer pathway (blood and urine, five areas of analysis, commonly 10–14+ targets, about 10–11 weeks to peptides, repeat testing 4–10 months); how targets are selected; factors that affect outcomes; no washout required before collection; routes of administration and home self-injection; how response is evaluated (symptoms, function, labs, imaging, cancer markers, ctDNA); “do not assume feeling worse means the therapy is working.”
• Neo7Bioscience. Molecular Surveillance and Personalized Engineering Overview (Provider Presentation, 2025/2026): the six-step patient journey from sample collection to treatment; the multi-omics layers for all patients and for cancer patients.